In metastatic PC, aberrant overexpression of OC2 promotes treatment resistance and transdifferentiation to neuroendocrine PC (NEPC) through repression of the androgen receptor (AR) axis, and activation of PEG10, a known NE driver28, as well as other oncogenic target genes. Here, AR is linked to pachyonychia congenita.